BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $3.04 EPS

Key Points

• BioCryst reported GAAP EPS of ($2.98), missing consensus by $3.04 largely due to a one‑time $698 million in‑process R&D charge from the Astria acquisition, while non‑GAAP results show operating profitability and pro forma liquidity of roughly $331 million.
• Q1 revenue of $156.4 million beat estimates and ORLADEYO net revenue was $148.3 million with patient prescriptions ahead of 2025 averages, but a manufacturing issue will delay initial pediatric pellet fulfillment—management says it does not expect the delay to change 2026 revenue guidance.
• Clinical progress supports future growth: navenibart’s ALPHA‑ORBIT pivotal enrollment should finish at ~145 patients next month (keeping a U.S. filing target by end‑2027), and BCX17725 has begun dosing in Phase I Part 4 with proof‑of‑concept data expected by year‑end.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04), FiscalAI reports. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The firm's revenue was up 7.5% compared to the same quarter last year.

Here are the key takeaways from BioCryst Pharmaceuticals' conference call:

• Strong commercial momentum: ORLADEYO net revenue was $148.3 million in Q1, with monthly new patient prescriptions slightly ahead of 2025 averages and early pediatric launch demand observed across all four pellet strengths.
• A manufacturing issue with ORLADEYO pediatric pellets will delay initial product fulfillment; the company says it does not expect the delay to change 2026 revenue guidance and will provide more timing details later this quarter.
• Development progress for navenibart is ahead of plan: ALPHA-ORBIT pivotal enrollment should complete by end of next month at ~145 patients, keeping a U.S. filing target by the end of 2027 and supporting a sizable injectable opportunity.
• Pipeline expansion: BCX17725 (KLK5 inhibitor) has started dosing in Part 4 of Phase I (up to 12 patients) with proof-of-concept data expected by year-end for Netherton syndrome.
• Mixed financial picture: GAAP was impacted by an in-process R&D charge of $698 million from the Astria asset acquisition, while non-GAAP results show strong operating profitability and pro forma liquidity of roughly $331 million after a $70 million upfront European license and a $400 million credit facility.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded down $0.23 during trading hours on Wednesday, hitting $8.81. The company's stock had a trading volume of 7,725,617 shares, compared to its average volume of 5,084,851. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31. The company's 50 day simple moving average is $9.03 and its two-hundred day simple moving average is $7.80. The company has a market cap of $2.24 billion, a P/E ratio of 7.34 and a beta of 0.57.

Insider Activity

In other news, insider Alane P. Barnes sold 150,000 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider owned 400,703 shares of the company's stock, valued at $3,666,432.45. This trade represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 40.8% during the 4th quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company's stock valued at $10,568,000 after buying an additional 392,521 shares during the period. Mackenzie Financial Corp increased its stake in shares of BioCryst Pharmaceuticals by 16.6% in the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company's stock worth $1,152,000 after purchasing an additional 21,411 shares in the last quarter. NewEdge Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $390,000. XTX Topco Ltd purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $133,000. Finally, Vestal Point Capital LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth $17,550,000. Institutional investors own 85.88% of the company's stock.

Key Headlines Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue beat and product sales growth—Q1 total revenue of $156.4M beat Street estimates, and ORLADEYO net revenue was $148.3M (+11% y/y; +21% y/y on a comparable basis excluding Europe), supporting the company’s top‑line momentum. BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Adjusted/operational EPS metrics looked better in some outlets—Zacks notes an adjusted Q1 loss of $0.03/share versus a $0.06 estimate, a small beat that investors focused on as evidence of underlying profitability trends. BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains—Needham lowered its price target from $18 to $16 but kept a Buy rating, signaling continued analyst conviction in longer‑term upside despite trimming expectations. Needham Lowers PT to $16 but Maintains Buy
• Neutral Sentiment: FY‑2026 revenue guidance largely in line with consensus—the company issued revenue guidance of $635M–$660M (consensus ~$648.7M), a band that overlaps Street expectations and leaves the outlook somewhat neutral overall. BioCryst Q1 Earnings / Guidance Details
• Neutral Sentiment: Small equity grants to new hires—company disclosed inducement RSUs totaling 61,750 shares; dilution is modest but worth noting for longer‑term capital structure. BioCryst Reports Inducement Grants
• Negative Sentiment: Large GAAP EPS miss and one‑time items—some reports (MarketBeat/press materials) show a GAAP EPS loss of ($2.98) that missed consensus by a wide margin, creating headline risk and investor concern over non‑operational charges or tax items driving the disparity between revenue strength and EPS. MarketBeat: Q1 Results and EPS Details
• Negative Sentiment: Conflicting headlines and investor uncertainty—differences between adjusted/operational metrics and GAAP results, plus follow‑up disclosures (slides and call PDFs), are increasing short‑term volatility as investors parse the causes. Q1 Slide Deck / Conference Materials

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCRX. Evercore began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. Weiss Ratings raised BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Wednesday, March 4th. Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a research note on Friday, January 30th. Finally, Needham & Company LLC decreased their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $20.10.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.